Drug intelligence / Profile preview

lysergic acid amide

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Lysergic acid amide is a naturally occurring psychoactive lysergamide of the ergoline family, structurally similar to lysergic acid diethylamide (LSD) but with lower potency and prominent sedative and vasoconstrictive effects.[2][6] It is found in significant and highly variable concentrations in seeds of several plants such as Argyreia nervosa (Hawaiian baby woodrose), Ipomoea tricolor, and Turbina (Rivea) corymbosa, where it is the predominant ergot alkaloid.[2][6] Lysergic acid amide acts primarily as a partial agonist at serotonin 5‑HT2A receptors and likely other serotonergic sites, producing psychedelic effects (euphoria, altered perception, hallucinations) together with frequent adverse effects including nausea, vomiting, tachycardia, and hypertension.[2] It has been marketed as a “legal high” and is sometimes used recreationally or experimentally for headache disorders such as cluster headache, but clinical data are limited and intoxications with severe neuropsychiatric and cardiovascular complications have been reported.[2]

Other names
ergined-lysergamidelysergic acid amideLSALAALA-111LA111LA 111
02

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)5-HT1R (5-HT1 receptor family)

Beyond the preview

Go deeper on lysergic acid amide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lysergic acid amide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call